AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-75835965/vertex-pharmaceuticals-inc-hiv.html" title="Facts and information about Vertex Pharmaceuticals Inc.(HIV protease inhibitor GW433908 clinical trial)(Brief Article)">Vertex Pharmaceuticals Inc.(HIV protease inhibitor GW433908 clinical trial)(Brief Article)</a>
Close
Set up an RSS feed that alerts you when new articles from Boston Business Journal are available.
Frequently asked questions about RSS feeds
Vertex Pharmaceuticals Inc.(HIV protease inhibitor GW433908 clinical trial)(Brief Article)
Cambridge-based Vertex Pharmaceuticals Inc. initiated a Phase III clinical trial of its investigational HIV protease inhibitor GW433908 (also known as 908), which it discovered through a joint research collaboration with GlaxoSmithKline (which will also license the product). In this randomized, open-label trial, …
Related articles from newspapers, magazines, journals, and more
-
- Vertex Pharmaceuticals reports that oral hepatitis C protease inhibitor,...
-
News wire article from: Asia Africa Intelligence Wire
May 17, 2005
700+ words
-
- GlaxoSmithKline and Vertex Pharmaceuticals announce virologic and drug...
-
News wire article from: Chemical Business Newsbase
September 28, 2006
700+ words
-
- GSK and Vertex Pharmaceuticals announce presentation of data supporting...
-
News wire article from: Chemical Business Newsbase
December 16, 2005
700+ words
-
- Vertex Pharmaceuticals reports that VX-950, an investigational oral hepatitis...
-
News wire article from: Asia Africa Intelligence Wire
May 10, 2005
700+ words
-
- Vertex Pharmaceuticals announces advancement to Phase Ib clinical trial for...
-
News wire article from: Asia Africa Intelligence Wire
November 8, 2004
700+ words
